Literature DB >> 7053308

Plasma protein binding of phencyclidine.

H G Giles, W A Corrigall, V Khouw, E M Sellers.   

Abstract

In healthy male subjects (n = 12) phencyclidine (PCP) free fraction was 22.0 +/- 2.8 % (mean +/- SD). In male patients with mild to moderate alcoholic liver disease (n = 16) free fraction (23.0 +/- 3.4%) was of the same order as in healthy subjects although age and the concentrations of albumin, bilirubin, and high-density lipoproteins were different (P less than 0.05). Free fraction (76.2 /+- 0.06%) in fatty acid free human serum albumin (HSA, 4.4 gm/dl) was far greater than in plasma. Both the increased binding of PCP in plasma over HSA and the lack of a difference in PCP binding between normals and patients was associated with alpha 1-acid glycoprotein (alpha 1-AGP). This protein is an acute-phase reactant that binds cationic drugs and rises nonspecifically in a variety of diseases. Free fraction of PCP in alpha 1-AGP (75 mg/dl) was 36.4 +/- 1.7%. Half of the variance in PCP binding can be accounted for (r = 0.67, P less than 0.01) from percentage of free PCP = 39.24 - 2.18 (albumin) - 0.094 (alpha 1-AGP). Male rats (n = 14, weight = 251 +/- 7 gm) were alternatively assigned to pretreatment with either saline or alpha 1-AGP (11.6 mg) by cardiac puncture. PCP brain concentrations were reduced (11%, P less than 0.05) in the protein-treated group 5 min after cardiac 3H-PCP (0.17 mg) administration, demonstrating that increased plasma protein binding can reduce free drug concentration during the distribution phase and, thereby, the rate and extent of drug distribution.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7053308     DOI: 10.1038/clpt.1982.12

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

2.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

3.  The binding of ketamine to plasma proteins: emphasis on human plasma.

Authors:  P G Dayton; R L Stiller; D R Cook; J M Perel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.

Authors:  E Snoeck; A Van Peer; M Sack; M Horton; G Mannens; R Woestenborghs; R Meibach; J Heykants
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

Review 5.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.